Does insulin have a role in type 2 diabetes mellitus in 2026?
This clinical update by Dr Elmo Pretorius, Specialist physician and endocrinologist addresses the use of insulin in T2DM patients who are being treated with cardiorenal-safe therapies
Learning objectives
You will learn:
- Why cardiorenal-safe therapies still need to be paired with good glycaemic control
- How persistent hyperglycaemia continues to drive microvascular complications and long-term risk
- When to consider basal insulin in 2026 – especially as β-cell function declines
- Why insulin glargine U300 (IGla-300) is a practical basal choice (stable profile, less variability and lower hypoglycaemia risk) compared to first-generation basal insulins
- How to individualise HbA1c goals and treatment intensity across the patient’s changing profile.
ATTENTIONKindly note that if you attended the live webinar, you have already received 1 CPD point and will not be permitted to receive additional points for the report. Should this occur, the HPCSA will only record 1 CPD point from the live webinar, invalidating any additional CPD points from the report. Please note deNovo Medica ensures uploading of your CPD points to the HPCSA: please don't upload these yourself.
To access this module, please register or login: